Clinical Trial Update: A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects [Phase 1]

View source ↗

Summary

A Phase I, randomized, placebo-controlled study in healthy subjects evaluating safety, tolerability, pharmacokinetics, GI transit time, and pharmacodynamic biom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• GSK3179106

Snippet

Sponsor: GlaxoSmithKline | Conditions: Irritable Bowel Syndrome | Phase 1 | Status: COMPLETED